In this study, we showed that the administration of dapagliflozin, a potent and selective SGLT2 inhibitor, was associated with improvements in liver tests and metabolic laboratory variables in patients with NASH and T2DM over the course of 24 weeks. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.